India Pharma Exports Rise 9 Percent to $30.47 Billion in 2024‑25 Fiscal Year

India sees its pharmaceutical export value rise 9 percent to $30.47 billion in the 2024‑25 fiscal year, according to Commerce Secretary statements, marking a continued upward trend after a 125 percent increase over the past nine years.

Commerce Secretary highlighted that the growth is driven by strong demand for generic medicines in the United States and Europe, with Indian firms expanding capacity and securing new regulatory approvals to meet overseas market standards.

Pharmexcil reported a 6.8 percent rise in pharma exports during the first quarter of FY27, indicating momentum carries into the new fiscal year and suggesting the sector could surpass $35 billion by year‑end if trends continue.

Industry analysts say the export surge strengthens India's position as the world’s leading generic drug supplier, supports trade balance improvement, and may attract further foreign investment into domestic manufacturing and R&D facilities.